{"title":"儿童青光眼艾哈迈德瓣膜的olog增强：2-6年随访。","authors":"Adam Jacobson, Brenda L Bohnsack","doi":"10.1016/j.ogla.2025.06.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Determine 2- to 6-year outcomes of Ologen augmentation of Ahmed glaucoma devices (OAGDs) in children with glaucoma.</p><p><strong>Design: </strong>Retrospective interventional case series.</p><p><strong>Subjects: </strong>Children (<18 years of age) with glaucoma requiring surgery for intraocular pressure (IOP) control with at least 2 years of postoperative follow-up.</p><p><strong>Methods: </strong>Placement of OAGD between 2018 and 2022.</p><p><strong>Main outcome measures: </strong>Change in IOP, number of glaucoma medications and best-corrected visual acuity from preoperative to final follow-up, and success of surgery (complete defined as IOP 5 to 20 mmHg without additional medications, visually devastating complication or additional IOP-lowering surgeries, qualified success defined as above except IOP control was maintained ± glaucoma medications).</p><p><strong>Results: </strong>Forty eyes of 28 patients underwent OAGD at median age of 2.6 years (interquartile range [IQR], 0.6-7.8). Primary congenital glaucoma was the most common diagnosis (12 eyes of 9 patients), followed by glaucoma secondary to nonacquired ocular anomaly (11 eyes of 6 patients). Twenty-two eyes of 16 patients had prior glaucoma surgery (median 2, [interquatile range (IQR), 1-2]). Preoperative IOP was a median of 27 mmHg (IQR, 24-35) on a median of 3 (IQR, 2-3) glaucoma medications. At final follow-up (median 3.6 years [IQR, 2.9-4.3]), IOP (median, 15 mmHg [IQR, 13-17]) and glaucoma medications (median, 0 [IQR, 0-0]) were significantly decrease (P < 0.0001). Complete success at final follow-up was 55% (22 of 40 eyes) with 3- and 5-year survival rates of 75% (95% confidence interval [CI], 59-86) and 57% (95% CI, 35-74). Qualified success rate was 75% (30 of 40 eyes) with 3- and 5-year survival rates of 87% (95% CI, 71-95) and 67% (95% CI, 42-83), respectively.</p><p><strong>Conclusions: </strong>Although OAGD decreased IOP and the number of glaucoma medications, the high survival rates seen over the first 3 years decreased by 5 years.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":56368,"journal":{"name":"Ophthalmology. Glaucoma","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ologen-Augmentation of Ahmed Valves in Pediatric Glaucomas: 2- to 6-Year Follow-Up.\",\"authors\":\"Adam Jacobson, Brenda L Bohnsack\",\"doi\":\"10.1016/j.ogla.2025.06.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Determine 2- to 6-year outcomes of Ologen augmentation of Ahmed glaucoma devices (OAGDs) in children with glaucoma.</p><p><strong>Design: </strong>Retrospective interventional case series.</p><p><strong>Subjects: </strong>Children (<18 years of age) with glaucoma requiring surgery for intraocular pressure (IOP) control with at least 2 years of postoperative follow-up.</p><p><strong>Methods: </strong>Placement of OAGD between 2018 and 2022.</p><p><strong>Main outcome measures: </strong>Change in IOP, number of glaucoma medications and best-corrected visual acuity from preoperative to final follow-up, and success of surgery (complete defined as IOP 5 to 20 mmHg without additional medications, visually devastating complication or additional IOP-lowering surgeries, qualified success defined as above except IOP control was maintained ± glaucoma medications).</p><p><strong>Results: </strong>Forty eyes of 28 patients underwent OAGD at median age of 2.6 years (interquartile range [IQR], 0.6-7.8). Primary congenital glaucoma was the most common diagnosis (12 eyes of 9 patients), followed by glaucoma secondary to nonacquired ocular anomaly (11 eyes of 6 patients). Twenty-two eyes of 16 patients had prior glaucoma surgery (median 2, [interquatile range (IQR), 1-2]). Preoperative IOP was a median of 27 mmHg (IQR, 24-35) on a median of 3 (IQR, 2-3) glaucoma medications. At final follow-up (median 3.6 years [IQR, 2.9-4.3]), IOP (median, 15 mmHg [IQR, 13-17]) and glaucoma medications (median, 0 [IQR, 0-0]) were significantly decrease (P < 0.0001). Complete success at final follow-up was 55% (22 of 40 eyes) with 3- and 5-year survival rates of 75% (95% confidence interval [CI], 59-86) and 57% (95% CI, 35-74). Qualified success rate was 75% (30 of 40 eyes) with 3- and 5-year survival rates of 87% (95% CI, 71-95) and 67% (95% CI, 42-83), respectively.</p><p><strong>Conclusions: </strong>Although OAGD decreased IOP and the number of glaucoma medications, the high survival rates seen over the first 3 years decreased by 5 years.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>\",\"PeriodicalId\":56368,\"journal\":{\"name\":\"Ophthalmology. Glaucoma\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Glaucoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ogla.2025.06.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Glaucoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ogla.2025.06.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Ologen-Augmentation of Ahmed Valves in Pediatric Glaucomas: 2- to 6-Year Follow-Up.
Purpose: Determine 2- to 6-year outcomes of Ologen augmentation of Ahmed glaucoma devices (OAGDs) in children with glaucoma.
Design: Retrospective interventional case series.
Subjects: Children (<18 years of age) with glaucoma requiring surgery for intraocular pressure (IOP) control with at least 2 years of postoperative follow-up.
Methods: Placement of OAGD between 2018 and 2022.
Main outcome measures: Change in IOP, number of glaucoma medications and best-corrected visual acuity from preoperative to final follow-up, and success of surgery (complete defined as IOP 5 to 20 mmHg without additional medications, visually devastating complication or additional IOP-lowering surgeries, qualified success defined as above except IOP control was maintained ± glaucoma medications).
Results: Forty eyes of 28 patients underwent OAGD at median age of 2.6 years (interquartile range [IQR], 0.6-7.8). Primary congenital glaucoma was the most common diagnosis (12 eyes of 9 patients), followed by glaucoma secondary to nonacquired ocular anomaly (11 eyes of 6 patients). Twenty-two eyes of 16 patients had prior glaucoma surgery (median 2, [interquatile range (IQR), 1-2]). Preoperative IOP was a median of 27 mmHg (IQR, 24-35) on a median of 3 (IQR, 2-3) glaucoma medications. At final follow-up (median 3.6 years [IQR, 2.9-4.3]), IOP (median, 15 mmHg [IQR, 13-17]) and glaucoma medications (median, 0 [IQR, 0-0]) were significantly decrease (P < 0.0001). Complete success at final follow-up was 55% (22 of 40 eyes) with 3- and 5-year survival rates of 75% (95% confidence interval [CI], 59-86) and 57% (95% CI, 35-74). Qualified success rate was 75% (30 of 40 eyes) with 3- and 5-year survival rates of 87% (95% CI, 71-95) and 67% (95% CI, 42-83), respectively.
Conclusions: Although OAGD decreased IOP and the number of glaucoma medications, the high survival rates seen over the first 3 years decreased by 5 years.
Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
